Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;3(3):182-8.
doi: 10.3978/j.issn.2078-6891.2012.018.

Molecular pathology of pancreatic neuroendocrine tumors

Mingyi Chen  1 , Michael Van Ness, Yangtong Guo, Jeffrey Gregg
Affiliations

Molecular pathology of pancreatic neuroendocrine tumors

Mingyi Chen et al. J Gastrointest Oncol. 2012 Sep.

Abstract

Pancreatic endocrine tumors (PETs) are rare neoplasms which account for 1% to 2% of all pancreatic malignancies. The diagnostic, grading and prognostic criteria for PETs have been controversial in surgical pathology and clinical medicine. The newly updated 2010 WHO classification introduced in clinical practice will give more insight into genetic and molecular changes related to PET subtypes. These neoplasms can be graded into 1 of 3 tiers, based on histologic characteristics in likeness to epithelial neuroendocrine tumors in other anatomic sites. Most PETs are sporadic, however, some of them, may occur as part of familial tumors (inherited syndromes) such as multiple endocrine neoplasia type 1 (MEN1 syndrome), von Hippel-Lindau disease (VHL), neurofibromatosis type 1 (NF-1), and tuberous sclerosis (TSC). In sporadic endocrine pancreatic tumors, losses of chromosome 1 and 11q as well as gain on 9q appear to be early events in the development of pancreatic tumors. Multiple genetic defects may accumulate with time and result in pancreatic neuroendocrine tumor progression and malignancy. Although PETs may be similar or identical in histologic appearance to neuroendocrine tumors of the gastrointestinal tract, differences in their underlying biology and likely differences in response to therapeutic agents suggest that they should be treated and investigated as a distinct entity. The correlation of PI3K/Akt/mTOR pathway in the pathogenesis of PETs has been reported, and clinical trials data of mTOR inhibitors is promising.

Keywords: Pancreatic neuroendocrine tumors (PNET); molecular pathology and diagnosis; tumorigenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A. H&E stained section of a well-differentiated pancreatic neuroendocrine tumor (G1) showing an organoid/nested growth pattern; B. immunostaining revealed low Ki-67 (<2%); C. strong expression of synaptophysin; D. weak expression of insulin. (A, hematoxylin-eosin, original magnification ×40; C-D, immunohistochemistry, original magnification ×200)
See this image and copyright information in PMC

References

    1. Heitz PU KP, Perren A, Klimstra D, et al. Tumors of the endocrine pancreas. In: DeLellis RA LR, Heitz PU, Eng C eds. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: France IARC Press, 2004:175-208.
    1. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23:824-33 - PubMed
    1. Wick MR, Graeme-Cook FM. Pancreatic neuroendocrine neoplasms: a current summary of diagnostic, prognostic, and differential diagnostic information. Am J Clin Pathol 2001;115:S28-45 - PubMed
    1. Davì MV, Falconi M. Pancreas: Insulinoma--new insights into an old disease. Nat Rev Endocrinol 2009;5:300-2 - PubMed
    1. Rindi G, Wiedenmann B.Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 2011;8:54-64 - PubMed